Ascelia Pharma AB (publ) (ACE.ST)
SEK 3.1
(-2.36%)
SEK 3.1
(-2.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.04 Million SEK | 73.05% |
| 2022 | -3.89 Million SEK | 55.38% |
| 2021 | -8.72 Million SEK | -957.33% |
| 2020 | -825 Thousand SEK | -1230.65% |
| 2019 | -62 Thousand SEK | 97.53% |
| 2018 | -2.5 Million SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - SEK | 0.0% |
| 2024 Q2 | - SEK | 0.0% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q4 | - SEK | 0.0% |
| 2023 FY | -1.04 Million SEK | 73.05% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 FY | -3.89 Million SEK | 55.38% |
| 2022 Q3 | - SEK | 0.0% |
| 2022 Q4 | - SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 FY | -8.72 Million SEK | -957.33% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2020 FY | -825 Thousand SEK | -1230.65% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | -62 Thousand SEK | 97.53% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | -2.5 Million SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 99.347% |
| Ziccum AB (publ) | -23.28 Million SEK | 95.495% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.303% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 102.51% |
| Mendus AB (publ) | 28.48 Million SEK | 103.682% |
| Genovis AB (publ.) | 54 Million SEK | 101.943% |
| Intervacc AB (publ) | -13.79 Million SEK | 92.395% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 148.319% |
| Active Biotech AB (publ) | -1.67 Million SEK | 37.373% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 110.529% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 103.911% |
| Aptahem AB (publ) | 2.63 Million SEK | 139.876% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 69.336% |
| Kancera AB (publ) | -1.96 Million SEK | 46.616% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 1462.338% |
| Fluicell AB (publ) | 1.73 Million SEK | 160.357% |
| Saniona AB (publ) | 11.78 Million SEK | 108.904% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 79.5% |
| Biovica International AB (publ) | 6.87 Million SEK | 115.254% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 95.495% |
| AcouSort AB (publ) | 8.38 Million SEK | 112.504% |
| Xintela AB (publ) | 78 Thousand SEK | 1444.872% |
| Abliva AB (publ) | -35.66 Million SEK | 97.059% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 99.286% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 137.371% |
| OncoZenge AB (publ) | 3000.00 SEK | 35066.667% |
| Amniotics AB (publ) | -1.93 Million SEK | 45.648% |
| 2cureX AB (publ) | -37.48 Million SEK | 97.202% |
| CombiGene AB (publ) | -21.29 Million SEK | 95.073% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -147.991% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.093% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.066% |
| Corline Biomedical AB | 28.38 Million SEK | 103.696% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 99.145% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 96.952% |
| I-Tech AB | 27.56 Million SEK | 103.805% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 101.478% |
| Cyxone AB (publ) | 2.61 Million SEK | 140.176% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 130.826% |
| Biosergen AB | -456 Thousand SEK | -130.044% |
| Cantargia AB (publ) | -3.45 Million SEK | 69.603% |
| NextCell Pharma AB | -43.74 Million SEK | 97.602% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 88.59% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 109.351% |
| Nanologica AB (publ) | -76 Thousand SEK | -1280.263% |
| SynAct Pharma AB | -778 Thousand SEK | -34.833% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -443.523% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 91.882% |
| Lipum AB (publ) | 53 Thousand SEK | 2079.245% |
| BioInvent International AB (publ) | 71.46 Million SEK | 101.468% |
| Alzinova AB (publ) | 19.87 Million SEK | 105.278% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 102.89% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 171.701% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -6893.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 163.269% |
| Simris Alg AB (publ) | 2 Million SEK | 152.267% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 70.698% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 102.964% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 133.482% |